<DOC>
	<DOC>NCT00787917</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.</brief_summary>
	<brief_title>An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Aspergillosis, Allergic Bronchopulmonary</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Diagnosis of Cystic Fibrosis complicated by Allergic Bronchopulmonary Aspergillosis (ABPA) Oral corticosteroid use for ABPA flare Age 12 years and older (except for Italy; ≥ 18 years) Total serum IgE levels ≥ 500 IU/mL History of cancer in the last 10 years. History of severe allergic reactions Pregnant and lactating women Prior use of Xolair Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Allergic Bronchopulmonary Aspergillosis</keyword>
	<keyword>omalizumab</keyword>
	<keyword>oral corticosteroid use</keyword>
	<keyword>anti-immunoglobulin E</keyword>
</DOC>